Therapy of hypoparathyroidism with PTH(1-84): A prospective four-year investigation of efficacy and safety

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 1, 2013, Pages 137-144

  Cusano, Natalie E ^a   Rubin, Mishaela R ^a   McMahon, Donald J ^a   Zhang, Chiyuan ^a   Ives, Rebecca ^a   Tulley, Amanda ^a   Sliney, James ^a   Cremers, Serge C ^a   Bilezikian, John P ^a  

^a Division of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; OSTEOCALCIN; PHOSPHORUS; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; RECOMBINANT PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ELBOW FRACTURE; EXCRETION; FATIGUE; FEMALE; FOOT FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; HYPERCALCEMIA; HYPOPARATHYROIDISM; INFECTION; INSOMNIA; LUMBAR SPINE; MALE; MENTAL DISEASE; MOOD DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHOSPHORUS EXCRETION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIUS; SIDE EFFECT; SKIN DISEASE; STEADY STATE; THIRST; TREATMENT DURATION; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

EID: 84872084273     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2984     Document Type: Article

References (20)

1. Bilezikian JP, Khan A, Potts Jr JT, Brandi ML, Clarke BL, Shoback D, Jüppner H, D'Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J 2011 Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res 26:2317-2337
2. Cusano NE, Rubin MR, Sliney Jr J, Bilezikian JP 2012 Mini-review: new therapeutic options in hypoparathyroidism. Endocrine 41:410-414
3. Shoback D 2008 Clinical practice. Hypoparathyroidism. N Engl J Med 359:391-403
4. Mitchell DM, Regan S, Cooley MR, Lauter KB, Vrla MC, Becker CB, Burnett-Bowie SM, Mannstadt M, Long-term follow-up of patients with hypoparathyroidism - a cohort study. Program of the 94th Annual Meeting of The Endocrine Society, Houston, TX, 2012 (Abstract OR27-2)
5. Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler Jr GB 2003 Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 88:4214-4220
6. Winer KK, Zhang B, Shrader JA, Peterson D, Smith M, Albert PS, Cutler Jr GB 2012 Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab 97:391-399
7. Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L 2011 The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res 26:2358-2370
8. Rubin MR, Bilezikian JP 2010 Hypoparathyroidism: clinical features, skeletal microstructure and parathyroid hormone replacement. Arq Bras Endocrinol Metabol 54:220-226
9. Bilezikian JP, Mosekilde L, Shoback D, Vokes T, Mannstadt M, Clarke B, Lagast H, Garceau R, Efficacy of recombinant human parathyroid hormone (rhPTH[1-84]) for the treatment of adults with hypoparathyroidism: a randomized, double-blind, placebo-controlled study. Program of the 94th Annual Meeting of The Endocrine Society, Houston, TX, 2012 (Abstract S18-3)
10. Schwietert HR, Groen EW, Sollie FA, Jonkman JH 1997 Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers. Clin Pharmacol Ther 61:360-376
11. Lindsay R, Nieves J, Henneman E, Shen V, Cosman F 1993 Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): kinetics and biochemical response in estrogenized osteoporotic patients. J Clin Endocrinol Metab 77:1535-1539
12. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, Seldin D, Jacobs TP, Siris ES, Cafferty M, Parisien MV, Lindsay R, Clemens TL, Bilezikian JP 1989 Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4:283-291
13. Bilezikian JP, Brandi ML, Rubin M, Silverberg SJ 2005 Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features. J Intern Med 257:6-17
14. Dempster DW, Müller R, Zhou H, Kohler T, Shane E, Parisien M, Silverberg SJ, Bilezikian JP 2007 Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 41:19-24
15. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
16. Rubin MR, Cosman F, Lindsay R, Bilezikian JP 2002 The anabolic effects of parathyroid hormone. Osteoporos Int 13:267-277
17. Rubin MR, Dempster DW, Sliney Jr J, Zhou H, Nickolas TL, Stein EM, Dworakowski E, Dellabadia M, Ives R, McMahon DJ, Zhang C, Silverberg SJ, Shane E, Cremers S, Bilezikian JP 2011 PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res 26:2727-2736
18. Clausen JO 2009 Comment on Kanis et al: "European guidance for the diagnosis and management of osteoporosis in postmenopausal women." Osteoporos Int 20:1631
19. Sikjaer T, Rejnmark L, Rolighed L, Mosekilde L, PTH(1-84) replacement therapy in hypoparathyroidism (HypoPT): a randomized controlled trial on pharmacokinetics and dynamic effects following 24 weeks of treatment. Program of the 33rd Annual Meeting of the American Society of Bone and Mineral Research, San Diego, CA, 2011 (Abstract 1098)
20. Fox J, Wells D, Garceau R, Relationships between pharmacokinetic profile of human PTH(1-84) and serum calcium response in postmenopausal women following 4 different methods of administration. Program of the 33rd Annual Meeting of the American Society of Bone and Mineral Research, San Diego, CA, 2011 (Abstract MO0173)